Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Rituximab (R) Maintenance Versus Observation After Short Term Chemoimmunotherapy R-FND as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Updated Results and Safety of the Maintenance of An Intergruppo Italiano Linfomi (IIL) Randomized Trial.

Blood (2009) 114 (22): 1706.

https://doi.org/10.1182/blood.V114.22.1706.1706

Published: 2009

Journal Articles

Phase II Multicenter Study of Association of Arsenic Trioxide (ATO) and Ascorbic Acid in Myelodysplastic Syndrome.

Blood (2009) 114 (22): 943.

https://doi.org/10.1182/blood.V114.22.943.943

Published: 2009

Journal Articles

Allogeneic Stem Cell Transplantation (Allo-SCT) Following a Reduced-Intensity Conditioning (RIC) Regimen in Relapsed Peripheral T-Cell Lymphomas (PTCL): Results at 4 Year of Median Follow-up.

Anna Dodero, Francesco Spina, MD, Franco Narni, Francesca Patriarca, Sergio Cortelazzo, MD, Fabio Benedetti, Fabio Ciceri, M.D., Donatella Baronciani, Rosanna Scime', MD, Enrico Pogliani, MD, Alessandro Rambaldi, MD, Francesca Bonifazi, MD, Attilio Olivieri, MD, Benedetto Bruno, Corrado Tarella, Paolo Corradini

Blood (2009) 114 (22): 875.

https://doi.org/10.1182/blood.V114.22.875.875

Published: 2009

Journal Articles

Caspofungin Primary Antifungal Prophylaxis in Acute Leukemia Patients During Induction Therapy: Results of a Prospective Phase II Multicentric Study (ProfilC Study).

Blood (2009) 114 (22): 1638.

https://doi.org/10.1182/blood.V114.22.1638.1638

Published: 2009

Journal Articles

Cerebrospinal Fluid Flow Cytometry Analysis in Newly Diagnosed Aggressive Non-Hodgkin Lymphomas at High Risk for Leptomeningeal Disease: Result of a Multicentric Prospective Italian Study.

Giulia Benevolo, Pietro Pioltelli, Michele Spina, Barbara Botto, Alessandra Stacchini, Andrea Evangelista, Pietro Bulian, Francesco Mannelli, Maria Cantonetti, Alice Di Rocco, Lorella Depaoli, Vincenzo Pavone, Nicola Di Renzo, Andres Ferreri, Marcella Arras, Enrico Pogliani, Umberto Vitolo

Blood (2009) 114 (22): 2919.

https://doi.org/10.1182/blood.V114.22.2919.2919

Published: 2009

Journal Articles

Brief Chemoimmunotherapy Rituximab (R)-FND ± R Maintenance as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Preliminary Analysis of a Prospective Randomized IIL Trial

Blood (2008) 112 (11): 834.

https://doi.org/10.1182/blood.V112.11.834.834

Published: 2008

Journal Articles

Long-Term Follow-up of Patients Affected by Relapsed Lymphomas Receiving Reduced-Intensity Conditioning (RIC) Regimen Followed by Allogeneic Stem Cell Transplantation (Allo-SCT): An Update of the Phase II Study of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO)

Blood (2008) 112 (11): 3303.

https://doi.org/10.1182/blood.V112.11.3303.3303

Published: 2008

Journal Articles

The Impact of Therapeutic Management and Prognostic Factors on the Outcome of Primary Cutaneous B-Cell Lymphomas (PCBCL) (IELSG 11 Study)

Blood (2008) 112 (11): 3608.

https://doi.org/10.1182/blood.V112.11.3608.3608

Published: 2008

Journal Articles

Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage

Blood (2008) 111 (8): 4004–4013.

https://doi.org/10.1182/blood-2007-10-116749

Published: 2008

Journal Articles

Secondary Antifungal Prophylaxis with Liposomal Amphotericin B (AmB-L) in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

Alessandro Busca, MD, Stefano D’Ardia, MD, Elisabetta Terruzzi, MD, Enrico Pogliani, MD, Emilio Paolo Alessandrino, MD, Vassiliki Griva, MD, Giorgio Lambertenghi Deliliers

Blood (2007) 110 (11): 4972.

https://doi.org/10.1182/blood.V110.11.4972.4972

Published: 2007

Journal Articles

Minimal Residual Disease (MRD)-Oriented Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Results of Northern Italy Leukemia Group Study 09/00.

Renato Bassan, MD, Orietta Spinelli, BSc, Elena Oldani, BSc, Tamara Intermesoli, MD, Manuela Tosi, BSc, Barbara Peruta, BSc, Vittoria Guerini, BSc, Giuseppe Rossi, MD, Enrico Pogliani, MD, Eros Di Bona, MD, Pietro Fabris, MD, Agostino Cortelezzi, MD, Teodoro Chisesi, MD, Emanuele Angelucci, MD, Franco Leoni, MD, Fabio Ciceri, MD, Daniele Mattei, MD, Tiziano Barbui, MD, Alessandro Rambaldi, MD

Blood (2007) 110 (11): 3497.

https://doi.org/10.1182/blood.V110.11.3497.3497

Published: 2007

Journal Articles

Long-Term Follow-Up of the Randomized GITMO/IIL Trial Comparing CHOP-Rituximab vs. High-Dose Therapy with Rituximab (R-HDS) in High Risk Follicular Lymphoma (Fl): Updated Results Suggest the Use of R-HDS as Salvage Treatment.

Blood (2007) 110 (11): 20.

https://doi.org/10.1182/blood.V110.11.20.20

Published: 2007

Journal Articles

Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia

Blood (2007) 110 (3): 840–846.

https://doi.org/10.1182/blood-2006-12-064287

Published: 2007

Includes: Supplemental data

Journal Articles

Infusion of Donor Derived Cytokine Induced Killer Cells May Induce Clinical Remission with Limited GVHD in Patients Relapsing after Allogeneic Stem Cell Transplantation.

Martino Introna, MD, Gianmaria Borleri, Elena Conti, Anna M. Barbui, MD, Raewyn Broady, BSc, Erica Dander, BSc, Giuseppe Gaipa, BSc, Giovanna D’Amico, BSc, Ettore Biagi, MD, Matteo Parma, MD, Enrico Pogliani, MD, Orietta Spinelli, BSc, Donatella Baronciani, MD, Anna Grassi, MD, Josee Golay, PhD, Tiziano Barbui, MD, Andrea Biondi, MD, Alessandro Rambaldi, MD

Blood (2006) 108 (11): 3698.

https://doi.org/10.1182/blood.V108.11.3698.3698

Published: 2006

Journal Articles

Clinical and Molecular Results of the Multicenter Randomized GITMO-IIL Trial in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Rituximab-Supplemented High-Dose Sequential Chemotherapy (R-HDS) Is Superior to CHOP-R in Molecular Remissions Rate, EFS and PFS.

Blood (2006) 108 (11): 325.

https://doi.org/10.1182/blood.V108.11.325.325

Published: 2006

Journal Articles

Rituximab-Supplemented High-Dose Sequential Chemotherapy (HDS) Has Superior Response Rate and Event-Free Survival (EFS) Compared to R-CHOP in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Results from a Multicenter Randomized GITMO Trial.

Blood (2005) 106 (11): 675.

https://doi.org/10.1182/blood.V106.11.675.675

Published: 2005

Journal Articles

Effect of Adding Rituximab (R) to Induction Treatment and High Dose Chemotherapy (HDC) Prior to Autologous Stem Cell Transplantation (ASCT) as First Line Therapy in Stage III-IV Diffuse Large B-Cell Lymphoma (B-DLCL) at Poor Prognosis.

Blood (2005) 106 (11): 676.

https://doi.org/10.1182/blood.V106.11.676.676

Published: 2005

Journal Articles

Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report

Miriam Galbusera, Elena Bresin, Marina Noris, Sara Gastoldi, Daniela Belotti, Cristina Capoferri, Erica Daina, Paolo Perseghin, Friedrich Scheiflinger, Fadi Fakhouri, Jean-Pierre Grünfeld, Enrico Pogliani, Giuseppe Remuzzi

Blood (2005) 106 (3): 925–928.

https://doi.org/10.1182/blood-2004-12-4885

Published: 2005

Journal Articles

A Predictive Model for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Analysis of 1,252 Cases Performed by the Intergruppo Italiano Linfomi (IIL).

Sergio Cortelazzo, MD, Stefano Luminari, MD, Monica Bellei, PhD, Maurizio Martelli, MD, Umberto Vitolo, MD, Luigi Rigacci, MD, Achille Ambrosetti, MD, Enrico Pogliani, MD, Teodoro Chisesi, MD, Giorgio Rossi, MD, Andrea Rossi, MD, Alessandro Rambaldi, MD, Tiziano Barbui, MD, Maura Brugiatelli, MD, Massimo Federico

Blood (2004) 104 (11): 3261.

https://doi.org/10.1182/blood.V104.11.3261.3261

Published: 2004

Journal Articles

Sequential Brief Chemo-Immunotherapy FND + Rituximab in Elderly Patients with Advanced Stage Follicular Lymphoma (FL): High Clinical and Molecular Remission Rate Associated with a Prolonged Failure-Free Survival.

Blood (2004) 104 (11): 1320.

https://doi.org/10.1182/blood.V104.11.1320.1320

Published: 2004

NARROW

Rituximab (R) Maintenance Versus Observation After Short Term Chemoimmunotherapy R-FND as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Updated Results and Safety of the Maintenance of An Intergruppo Italiano Linfomi (IIL) Randomized Trial.

Phase II Multicenter Study of Association of Arsenic Trioxide (ATO) and Ascorbic Acid in Myelodysplastic Syndrome.

Allogeneic Stem Cell Transplantation (Allo-SCT) Following a Reduced-Intensity Conditioning (RIC) Regimen in Relapsed Peripheral T-Cell Lymphomas (PTCL): Results at 4 Year of Median Follow-up.

Caspofungin Primary Antifungal Prophylaxis in Acute Leukemia Patients During Induction Therapy: Results of a Prospective Phase II Multicentric Study (ProfilC Study).

Cerebrospinal Fluid Flow Cytometry Analysis in Newly Diagnosed Aggressive Non-Hodgkin Lymphomas at High Risk for Leptomeningeal Disease: Result of a Multicentric Prospective Italian Study.

Brief Chemoimmunotherapy Rituximab (R)-FND ± R Maintenance as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Preliminary Analysis of a Prospective Randomized IIL Trial

Long-Term Follow-up of Patients Affected by Relapsed Lymphomas Receiving Reduced-Intensity Conditioning (RIC) Regimen Followed by Allogeneic Stem Cell Transplantation (Allo-SCT): An Update of the Phase II Study of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO)

The Impact of Therapeutic Management and Prognostic Factors on the Outcome of Primary Cutaneous B-Cell Lymphomas (PCBCL) (IELSG 11 Study)

Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage

Secondary Antifungal Prophylaxis with Liposomal Amphotericin B (AmB-L) in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

Minimal Residual Disease (MRD)-Oriented Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Results of Northern Italy Leukemia Group Study 09/00.

Long-Term Follow-Up of the Randomized GITMO/IIL Trial Comparing CHOP-Rituximab vs. High-Dose Therapy with Rituximab (R-HDS) in High Risk Follicular Lymphoma (Fl): Updated Results Suggest the Use of R-HDS as Salvage Treatment.

Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia

Infusion of Donor Derived Cytokine Induced Killer Cells May Induce Clinical Remission with Limited GVHD in Patients Relapsing after Allogeneic Stem Cell Transplantation.

Clinical and Molecular Results of the Multicenter Randomized GITMO-IIL Trial in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Rituximab-Supplemented High-Dose Sequential Chemotherapy (R-HDS) Is Superior to CHOP-R in Molecular Remissions Rate, EFS and PFS.

Rituximab-Supplemented High-Dose Sequential Chemotherapy (HDS) Has Superior Response Rate and Event-Free Survival (EFS) Compared to R-CHOP in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Results from a Multicenter Randomized GITMO Trial.

Effect of Adding Rituximab (R) to Induction Treatment and High Dose Chemotherapy (HDC) Prior to Autologous Stem Cell Transplantation (ASCT) as First Line Therapy in Stage III-IV Diffuse Large B-Cell Lymphoma (B-DLCL) at Poor Prognosis.

Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report

A Predictive Model for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Analysis of 1,252 Cases Performed by the Intergruppo Italiano Linfomi (IIL).

Sequential Brief Chemo-Immunotherapy FND + Rituximab in Elderly Patients with Advanced Stage Follicular Lymphoma (FL): High Clinical and Molecular Remission Rate Associated with a Prolonged Failure-Free Survival.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only